Buffett sees BMY as a good business with strong cash economics: $15 B operating cash flow and >70% gross margin confirm pricing power. However, the need for constant R&D reinvestment and episodic write-downs make future earnings less predictable. He values predictability above all. The 2024 impairment and equity drop from $29.5 B to $16.4 B signal weak capital discipline, reducing confidence in long-term compounding. The moat—patents, regulation, physician loyalty—is sound but not permanent. Buffett would treat BMY as a defensive income stock, not a compounding franchise. He requires a clear 30% margin of safety before purchase, translating to a buy zone below $45 given fair value $60–65.</p><p>Buffett disagrees with Tepper’s sentiment-driven optimism, emphasizing that valuation must rest on predictable owner earnings, not market reaction. He challenges Vinall’s compounding thesis, noting that reinvestment returns are modest; the business preserves value but rarely multiplies it. He cautions Munger against assuming impairments are purely temporary, reminding that management’s history of overpaying for acquisitions undermines intrinsic value.</p><p>Wait for price ≤ $45 before accumulating. Engage management on capital allocation and impairment discipline. Monitor 10-year cash flow predictability and ROIC stability before full ownership.

Munger views BMY as a solid, understandable enterprise if one focuses on cash flows rather than scientific complexity. The business earns high margins and stable cash, but management’s history of impairments shows poor judgment. He appreciates the oligopolistic industry structure and essential demand but dislikes the binary nature of R&D outcomes. Predictability is moderate, not high. Munger values intelligent patience: he would wait for market panic or impairment-driven selloff to buy, ensuring asymmetric upside. He believes the moat is real but narrowing; reinvestment discipline must improve for long-term compounding.</p><p>Munger disputes Buffett’s hesitation on complexity, arguing that cash flow stability outweighs scientific uncertainty. He challenges Kantesaria’s avoidance stance, noting that essential healthcare demand ensures survival even through patent cycles. He questions Vinall’s optimism on compounding, emphasizing that BMY is a value play, not a growth machine.</p><p>Wait for sentiment-driven discount below $43. Buy opportunistically during impairment-driven drawdowns. Reassess management discipline annually before long-term hold.

Kantesaria demands inevitability, not predictability. BMY’s dependence on patent renewal violates his 10–20 year visibility requirement. He notes that ROIC barely exceeds cost of capital and equity erosion signals reinvestment inefficiency. The moat is temporary—patent-based rather than structural. Without permanent advantages, compounding cannot be trusted. He avoids until management demonstrates durable reinvestment at high ROIC and reduced acquisition risk.</p><p>Kantesaria disagrees with Munger’s opportunistic stance, arguing that temporary mispricing cannot offset structural unpredictability. He challenges Buffett’s confidence in cash flow stability, noting that patent cliffs make long-term forecasts unreliable. He cautions Vinall that reinvestment merely maintains the moat rather than expanding it.</p><p>Exclude BMY from long-duration portfolio. Reassess after 3–5 years of stable pipeline success. Focus on businesses with permanent moats and predictable reinvestment.

Tepper sees BMY as a defensive large-cap with strong liquidity and predictable demand. The 4.6% dividend and low beta make it suitable for tactical accumulation. He interprets 2024’s loss as a non-cash event likely to trigger institutional de-risking, creating temporary mispricing. Operating cash flow $15 B and manageable debt coverage ensure downside protection. He focuses on sentiment extremes rather than intrinsic value, expecting mean reversion once impairments are absorbed.</p><p>Tepper disputes Buffett’s insistence on predictability, arguing that volatility creates opportunity. He challenges Kantesaria’s avoidance, noting that uncertainty can be priced cheaply enough to yield asymmetric upside. He disagrees with Prasad’s survival-only lens, emphasizing that policy tailwinds can amplify short-term returns.</p><p>Track institutional selling and liquidity dislocations. Buy during impairment-driven drawdowns below $45. Exit once sentiment normalizes or policy tailwinds fade.

Vinall views BMY as a potential compounding machine if R&D reinvestment yields durable new franchises. The business has scale and cash generation but uncertain reinvestment quality. He notes that free cash flow conversion >90% in normal years indicates strong underlying economics. Equity shrinkage and impairments suggest poor capital discipline, limiting compounding potential. He holds until reinvestment efficiency and pipeline success confirm sustainable growth.</p><p>Vinall disagrees with Kantesaria’s avoidance, arguing that BMY could evolve into a compounding franchise if management improves discipline. He challenges Buffett’s pessimism on predictability, noting recurring drug demand provides a stable base. He disputes Munger’s purely opportunistic stance, preferring long-term ownership once reinvestment returns improve.</p><p>Hold position until reinvestment metrics improve. Reassess valuation after 2–3 years of consistent pipeline success. Accumulate below $45 for long-term compounding potential.

Pabrai treats BMY as an asymmetric bet during panic periods. Despite 2024’s loss, operating cash flow $15 B confirms survival value far above market fears. He values downside protection first, noting tangible book and cash reserves provide floor near $40. Healthcare demand is non-cyclical; bankruptcy risk negligible. This makes deep value entry attractive. He would buy only when sentiment prices the stock as distressed, capturing 3× upside potential.</p><p>Pabrai disputes Kantesaria’s avoidance, arguing that uncertainty is opportunity if priced correctly. He challenges Buffett’s conservatism, noting that volatility can be a friend when downside is limited. He disagrees with Prasad’s evolutionary patience, emphasizing crisis-driven asymmetry as key to returns.</p><p>Wait for extreme pessimism or impairment-driven discount below $40. Enter small position with 3:1 payoff expectation. Exit when valuation normalizes or impairment reversed.

Prasad views BMY as an evolutionary survivor in a slow-changing industry. Despite impairments, the firm’s core cash engine remains intact. He values resilience over growth; steady $15 B OCF and >70% gross margin confirm survival fitness. Leverage and equity erosion are concerns but manageable if management deleverages and stabilizes ROIC. He holds until proof of sustained ROIC and disciplined capital allocation emerges.</p><p>Prasad disagrees with Tepper’s opportunism, emphasizing that survival quality, not sentiment, determines long-term success. He challenges Pabrai’s crisis focus, noting that evolutionary resilience merits ownership even without panic pricing. He disputes Munger’s buy-lower timing, preferring evidence of continuity over volatility exploitation.</p><p>Hold position; monitor ROIC trend and debt levels. Buy below $45 once ROIC > 12% for two years. Reassess long-term ownership after 2026 pipeline outcomes.